News >

FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 15, 2019

Jane Huang, MD
Jane Huang, MD
The FDA has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least 1 prior therapy, according to BeiGene, the company manufacturing the agent.1

“We are very excited to receive the breakthrough therapy designation from the FDA,” said Jane Huang, MD, chief medical officer, Hematology, of BeiGene, in a press release. “Zanubrutinib has been designed to maximize BTK occupancy and minimize off-target effects. We believe that the breakthrough therapy designation underscores the potential of zanubrutinib as a meaningful treatment for patients with MCL who have received at least 1 prior therapy. More than 1300 patients worldwide have been treated with zanubrutinib, and it’s being developed in a broad clinical program that currently includes 7 phase III or pivotal trials conducted globally or in China.”

The designation is based on reported activity with zanubrutinib in MCL, which includes phase II data that were presented at the 2018 ASH Annual Meeting (NCT03206970). Results of a single-arm, open-label, multicenter Chinese trial demonstrated that the overall response rate (ORR) with the next-generation small molecule BTK inhibitor was 83.5%.2 Additionally, responses appeared to be durable. These data were also incorporated into a new drug application (NDA) in China for zanubrutinib in patients with relapsed/refractory MCL.

The 1-year progression-free survival (PFS) rate in patients who received zanubrutinib was 90% and the 2-year PFS was 82%. At a median follow-up of 35.9 weeks, the median PFS had not yet been reached.

In the study, 86 adult patients with MCL who had received 1 to 4 prior treatment regimens were treated with 160 mg twice daily of zanubrutinib until disease progression or unacceptable toxicity. The primary endpoint was ORR by an independent review committee using PET-based imaging, according to the Lugano classification.

Regarding patient characteristics, the median patient age was 60.5 years, and the disease status was refractory in 52.3% and relapsed in 47.7%. Seventy-eight patients (90.7%) had stage III/IV disease and 72 (83.7%) were intermediate or high risk by the Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index. Moreover, 7 patients (8.1%) had bulky disease >10 cm and 37 (43%) had disease >5 cm, and 12 patients (14%) had the blastoid variant of MCL. The median number of prior therapies was 2.

At the time of the data cutoff on March 27, 2018, 21 patients were off treatment, 13 of which were due to progressive disease and 6 because of adverse events (AEs). One patient discontinued treatment at the investigator’s discretion 1 month after starting zanubrutinib and 1 patient who achieved a complete response (CR) withdrew consent.

Eighty-five patients were evaluable for efficacy, and of the 71 patients with an ORR, the best ORR was a CR in 50 patients (58.8%), a partial response (PR) in 21 (24.7%), and stable disease in 2 patients (2.4%). Five patients discontinued treatment prior to the first disease assessment and 1 had no evidence of measurable disease at baseline.

The benefit with zanubrutinib was found to be consistent across subgroups, including patients with and without the blastoid variant form of MCL, those with and without bulky disease, and those who had <3 or 3 or more prior lines of therapy. The ORR among patients with the blastoid variant subtype was 75%.

A total of 28 patients (32.6%) had a grade 3 treatment-emergent adverse event (TEAE) regardless of causality; 6 patients (7.0%) discontinued zanubrutinib because of a TEAE. There were 4 deaths; 1 in the setting of infection, 1 due to pneumonia, 1 due to cerebral hemorrhage, and 1 because of a traffic accident. TEAEs of special interest included diarrhea (10.5%), hypertension (8.1%), and petechiae/purpura/contusion (4.7%).

The most frequent TEAEs included decreased neutrophil count (31.4%), upper respiratory tract infection (29.1%), rash (29.1%), decreased platelet count (22.1%), and decreased white blood cell (WBC) count (17.4%). Grade ≥3 TEAEs reported in at least 2 patients included decreased neutrophil count (11.6%), lung infection (5.8%), anemia (4.7%), and decreased WBC count (3.5%).

With respect to the performance of BTK inhibitors as a whole, investigators noted that distinctive AEs were observed in this trial: diarrhea was observed in 9 patients (10.5%), which were all grade 1/2 events. A major hemorrhage was observed in 1 patient (1.2%) with a blastoid variant of MCL who had intra-parenchymal central nervous system bleeding.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication